Han Ya-ling, Wang Xiao-zeng, Jing Quan-min, Wang Shou-li, Ma Ying-yan, Luan Bo
Department of Cardiology, Shenyang General Hospital of People's Liberation Army, Shenyang 110016, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Feb;34(2):123-6.
To Compare the efficacy and safety of Rapamycin (Cypher) and Paclitaxel (TAXUS) eluting stents for multi-vessel coronary diseases.
From June 2003 to December 2004, a total of 416 patients with multi-vessel coronary diseases were randomly treated with Rapamycin (n = 210) and Paclitaxel (n = 206) eluting stents. Patients with left main lesion, acute myocardial infarction, revascularization were not included. Acute and long-term outcomes were compared between the two groups.
Baseline clinical characteristics, including risk factors of coronary heart disease, coronary lesion type, heart function, rates of success and complication of percutaneous coronary intervention procedure in the two groups were comparable. Number of stents implanted was not significantly different between the two groups (3.24 +/- 1.25 vs 3.19 +/- 1.38, P > 0.05). Mean follow-up duration was (19.5 +/- 8.9) months. Follow-up rate (96.2 vs 95.1%), angina pectoris reoccurrence (4.0 vs 6.1%), restenosis (7.1 vs 9.6%), major adverse cardiac event (6.4 vs 8.8%) and event free survival (93.1 vs 91.3%) during follow-up were not significantly different between the two groups. Subacute stent thrombosis rate tended to be higher in Paclitaxel eluting stent group compared with Rapamycin eluting stent group (1.0% vs 0.5%, P > 0.05). At 6 to 9 months angiographic follow-up, the in-stent minimal lumen diameter (MLD) and the in-segment MLD were similar between the two groups.
Satisfactory acute and long term outcomes for patients with multi-vessel coronary disease were achieved by both Cypher and TAXUS stent implantation and the safety and efficacy of the two kinds of stents were comparable.
比较雷帕霉素（西罗莫司）洗脱支架（Cypher）和紫杉醇洗脱支架（TAXUS）治疗多支冠状动脉疾病的有效性和安全性。
2003年6月至2004年12月，共416例多支冠状动脉疾病患者被随机分为两组，分别接受雷帕霉素洗脱支架治疗（n = 210）和紫杉醇洗脱支架治疗（n = 206）。排除左主干病变、急性心肌梗死及血运重建患者。比较两组的急性和长期预后。
两组患者的基线临床特征，包括冠心病危险因素、冠状动脉病变类型、心功能、经皮冠状动脉介入治疗的成功率及并发症发生率等均具有可比性。两组植入支架数量差异无统计学意义（3.24±1.25 对3.19±1.38，P>0.05）。平均随访时间为（19.5±8.9）个月。随访率（96.2%对95.1%）、心绞痛复发率（4.0%对6.1%）、再狭窄率（7.1%对9.6%）、主要不良心脏事件发生率（6.4%对8.8%）及随访期间无事件生存率（93.1%对91.3%）在两组间差异均无统计学意义。紫杉醇洗脱支架组亚急性支架内血栓形成率有高于雷帕霉素洗脱支架组的趋势（1.0%对0.5%，P>0.05）。在6至9个月的血管造影随访中，两组支架内最小管腔直径（MLD）和节段内MLD相似。
Cypher支架和TAXUS支架植入治疗多支冠状动脉疾病患者均取得了满意的急性和长期预后，两种支架的安全性和有效性相当。
